Clinical Trials Logo

Leiomyoma clinical trials

View clinical trials related to Leiomyoma.

Filter by:

NCT ID: NCT02520414 Completed - Uterine Leiomyomas Clinical Trials

Symphion® System In-Office Study

Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of using the Symphion system in an office setting.

NCT ID: NCT02495311 Recruiting - Adenomyosis Clinical Trials

The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms

Start date: November 15, 2014
Phase:
Study type: Observational

The aim of this study is to assess the relationship between adenomyosis/myoma and lower urinary tract symptoms, sexual function and gastrointestinal symptoms.

NCT ID: NCT02472184 Completed - Uterine Fibroids Clinical Trials

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

Start date: October 2015
Phase: N/A
Study type: Interventional

This study will look at the optimal order in which to perform concurrent office hysteroscopy and endometrial biopsy in female patients who present for evaluation of abnormal uterine bleeding at a fibroid and endometriosis treatment center.

NCT ID: NCT02470741 Completed - Uterine Fibroids Clinical Trials

Pilot of Letrozole for Uterine Myomas

PLUM
Start date: July 2015
Phase: Phase 4
Study type: Interventional

PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).

NCT ID: NCT02465814 Completed - Leiomyoma Clinical Trials

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

ASTEROID 2
Start date: June 2015
Phase: Phase 2
Study type: Interventional

The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will be supplemented.

NCT ID: NCT02440750 Not yet recruiting - Uterine Fibroids Clinical Trials

Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women

Start date: June 2016
Phase: Phase 4
Study type: Interventional

The presence of a thin endometrium has an important role in allowing the best conditions for hysteroscopic surgery. The aim of this study is to evaluate the efficacy of a 21 day administration of 2 mg of dienogest versus ulipristal acetate 5 mg, in rapid endometrial preparation to operative hysteroscopy.

NCT ID: NCT02425878 Terminated - Uterine Fibroids Clinical Trials

Ulipristal Acetate 10 mg and Asisted Reproduction

Start date: October 19, 2015
Phase: Phase 3
Study type: Interventional

Demonstrate an 15% increase in the rate of clinical pregnancy in women with inoperable intramural fibroids not distorting the uterine cavity within a program OVD, after administration of uPA in a dose of 10 mg orally daily for 12 weeks

NCT ID: NCT02410018 Completed - Leiomyomata Clinical Trials

Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata

Start date: April 2015
Phase: N/A
Study type: Interventional

This is a prospective, pilot, open-label, uncontrolled, safety and effectiveness study of uterine artery embolization with OCL 503 in women with leiomyomata who are scheduled for hysterectomy.

NCT ID: NCT02392585 Completed - Uterine Myoma Clinical Trials

Single or Triple Uterine Tourniquet at Myomectomy

Start date: March 2015
Phase: N/A
Study type: Interventional

The aim of study is to compare triple tourniquet vs. single tourniquet to reduce blood loss at open myomectomy.

NCT ID: NCT02386137 Completed - Uterine Fibroid Clinical Trials

Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids

PERAGUS
Start date: July 22, 2015
Phase: N/A
Study type: Interventional

Magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU) ablation is increasingly being used worldwide to treat symptomatic uterine fibroids because of its excellent therapeutic efficacy in controlling symptoms and its excellent safety record. Despite the benefits, it should be recognized that MR HIFU ablation does not always yield good therapeutic outcomes. High signal intensity on T2-weighted MR images and a high volume transfer constant (or Ktrans) on dynamic contrast material-enhanced MR images are the most well-known risk factors for poor ablation outcomes as measured with the non-perfused volume (NPV) ratio (ie, NPV divided by fibroid volume). The aim of this study is to assess the influence of fibroid perfusion (evaluated by MRI and contrast enhanced ultrasound), apparent diffusion coefficient (evaluated by MR-diffusion imaging) and fibroid stiffness (evaluated by ARFI) on ablation efficiency during uterine fibroid treatment by MR-HIFU.